Medical Devices Japan

Japan Pharmacogenomic Testing for Psychiatry Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Japan Pharmacogenomic Testing for Psychiatry Market Industry Trends and Forecast to 2034: Segmented by (Test, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $29.7 Mn Placeholder estimate
Estimate 2025 $33.0 Mn 6.8% of the global market
Projected 2034 $83.6 Mn 153.7% Adds $50.7 Mn over 9 forecast years
CAGR 2025–2034 10.9% Faster than 64% of 173 Medical Devices markets here
Key players 5
  • Japan is 6.81% of the global market.
  • In APAC, the largest is China at $42.4 Mn.
  • Fastest growing: India at 13.3% a year.
  • Japan ranks 2nd of 10 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$50.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Pharmacogenomic Testing for Psychiatry Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $29.7 Mn — —
2025 (base) $33.0 Mn +$3.2 Mn —
2026 (forecast) $36.6 Mn +$3.6 Mn +10.9%
2027 (forecast) $40.5 Mn +$4.0 Mn +23%
2028 (forecast) $45.0 Mn +$4.4 Mn +36.4%
2029 (forecast) $49.9 Mn +$4.9 Mn +51.3%
2030 (forecast) $55.3 Mn +$5.4 Mn +67.7%
2031 (forecast) $61.3 Mn +$6.0 Mn +86%
2032 (forecast) $68.0 Mn +$6.7 Mn +106.3%
2033 (forecast) $75.4 Mn +$7.4 Mn +128.8%
2034 (forecast) $83.6 Mn +$8.2 Mn +153.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Japan Pharmacogenomic Testing for Psychiatry Market Analysis at a glance
Market size, 2025$33.0 Mn placeholder estimate
Forecast, 2034$83.6 Mn placeholder estimate
Growth (CAGR), 2025–203410.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest, application and end user (see all)
Key playersMyriad Genetics, Inc., Genomind, OneOme, Tempus, Thermo Fisher Scientific Inc. (see all)
Regulator in JapanPMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Japan Pharmacogenomic Testing for Psychiatry Market Analysis Executive Summary

Pharmacogenomic tests for psychiatry look at a person's genes to help doctors choose antidepressants and other mental health medicines that are likely to work.

Key segments of the pharmacogenomic Testing for Psychiatry market include test (Multi-Gene Panels and Single-Gene Tests) and application (Depression, Anxiety and ADHD).

Bar chart: Japan Pharmacogenomic Testing for Psychiatry market size, 2024–2034, placeholder estimates. $29.7 Mn in 2024, $33.0 Mn in 2025 and $83.6 Mn in 2034, 10.9% CAGR.
Japan Pharmacogenomic Testing for Psychiatry market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Japan Pharmacogenomic Testing for Psychiatry Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the pharmacogenomic Testing for Psychiatry market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the pharmacogenomic Testing for Psychiatry market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the pharmacogenomic Testing for Psychiatry market.

Competitive Landscape for Pharmacogenomic Testing for Psychiatry Market in Japan

The pharmacogenomic Testing for Psychiatry market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Pharmacogenomic Testing for Psychiatry Market in Japan

Pharmacogenomic Testing for Psychiatry in Japan: rules, payment and health figures

Medical devices are notified, certified or approved depending on their risk; the Pharmaceuticals and Medical Devices Agency (PMDA) reviews higher-risk devices for approval by the Ministry of Health, Labour and Welfare.⁠[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).⁠[2] Suicide rate: 16.5 per 100,000 people in 2023, the latest WHO figure for Japan.⁠[3]

[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[3] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how pharmacogenomic Testing for Psychiatry products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Japan.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Pharmacogenomic Testing for Psychiatry right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Pharmacogenomic Testing for Psychiatry in context

Japan compared

  • Suicide rate: 16.5 per 100,000 people (2023). World: 9.2 per 100,000 people (2023). Highest of the 15 countries we cover in APAC.[1]
  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[2]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[3]

[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 18 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

Free data on this topic

Inside Japan

Quick answers

Frequently asked questions

How big is the Pharmacogenomic Testing for Psychiatry market in Japan?
Placeholder estimate: about $33.0 Mn in 2025, rising to about $83.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pharmacogenomic Testing for Psychiatry market in Japan growing?
Placeholder estimate: about 10.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pharmacogenomic Testing for Psychiatry market report cover?
The report splits the market by test (Multi-Gene Panels, Single-Gene Tests), application (Depression, Anxiety, ADHD, Bipolar Disorder) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Pharmacogenomic Testing for Psychiatry market?
Key players include Myriad Genetics, Inc., Genomind, OneOme, Tempus and Thermo Fisher Scientific Inc..
What is driving the Pharmacogenomic Testing for Psychiatry market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the pharmacogenomic Testing for Psychiatry market. Governments and employers are investing more in mental health care.
Who regulates Pharmacogenomic Testing for Psychiatry in Japan?
Medical devices are notified, certified or approved depending on their risk; the Pharmaceuticals and Medical Devices Agency (PMDA) reviews higher-risk devices for approval by the Ministry of Health, Labour and Welfare. Source: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
How is healthcare paid for in Japan?
Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices). Source: Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
What does WHO report for Japan?
Suicide rate: 16.5 per 100,000 people in 2023, the latest WHO figure. Source: WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
How many people in Japan are 65 or older?
30.0% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 18 Nov 2026.
How much research is published on Pharmacogenomic Testing for Psychiatry?
PubMed lists 6 papers on Pharmacogenomic Testing for Psychiatry added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Japan

See all

Related on mental health and genomics

See the topic